644 related articles for article (PubMed ID: 16513106)
21. Amentoflavone, a biflavonoid from Biophytum sensitivum augments lymphocyte proliferation, natural killer cell and antibody dependent cellular cytotoxicity through enhanced production of IL-2 and IFN-gamma and restrains serum sialic acid and gamma glutamyl transpeptidase production in tumor - bearing animals.
Guruvayoorappan C; Kuttan G
J Exp Ther Oncol; 2007; 6(4):285-95. PubMed ID: 18038762
[TBL] [Abstract][Full Text] [Related]
22. Heteroaryl substituted titanocenes as potential anti-cancer drugs.
Sweeney N; Gallagher WM; Müller-Bunz H; Pampillón C; Strohfeldt K; Tacke M
J Inorg Biochem; 2006 Sep; 100(9):1479-86. PubMed ID: 16764931
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of an ionic titanocene tetrachloroferrate derivative against some solid experimental tumors.
Köpf-Maier P; Klapötke T
Arzneimittelforschung; 1989 Apr; 39(4):488-90. PubMed ID: 2751735
[TBL] [Abstract][Full Text] [Related]
24. Myelopoietic response in tumour-bearing mice by an aggregated polymer isolated from Aspergillus oryzae.
Justo GZ; Durán N; Queiroz ML
Eur J Pharmacol; 2000 Feb; 388(3):219-26. PubMed ID: 10675729
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapeutic potential of the volatile oils from Zanthoxylum rhoifolium Lam leaves.
da Silva SL; Figueiredo PM; Yano T
Eur J Pharmacol; 2007 Dec; 576(1-3):180-8. PubMed ID: 17716654
[TBL] [Abstract][Full Text] [Related]
26. Titanocene dichloride--the first metallocene with cancerostatic activity.
Köpf H; Köpf-Maier P
Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
[No Abstract] [Full Text] [Related]
27. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
[TBL] [Abstract][Full Text] [Related]
28. Chiral cyclopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathepsin B activity and as antitumoral agents.
Bincoletto C; Tersariol IL; Oliveira CR; Dreher S; Fausto DM; Soufen MA; Nascimento FD; Caires AC
Bioorg Med Chem; 2005 Apr; 13(8):3047-55. PubMed ID: 15781414
[TBL] [Abstract][Full Text] [Related]
29. β-1,3-Glucan given orally modulates immunomyelopoietic activity and enhances the resistance of tumour-bearing mice.
Torello CO; Souza-Queiroz J; Queiroz ML
Clin Exp Pharmacol Physiol; 2012 Mar; 39(3):209-17. PubMed ID: 22150790
[TBL] [Abstract][Full Text] [Related]
30. Antitumor organometallics. I. Activity of some diphenyltin(IV) and diphenylantimony(III) derivatives on in vitro and in vivo Ehrlich ascites tumor.
Bara A; Socaciu C; Silvestru C; Haiduc I
Anticancer Res; 1991; 11(4):1651-5. PubMed ID: 1836124
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C2- and C1-symmetrical Ti(IV) complexes of tetradentate diamine bis(phenolato) ligands: a new class of antitumor agents.
Peri D; Meker S; Shavit M; Tshuva EY
Chemistry; 2009; 15(10):2403-15. PubMed ID: 19156656
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Hep2 and HeLa cell proliferation in vitro and EAC tumor growth in vivo by Lapemis curtus (Shaw 1802) venom.
Karthikeyan R; Karthigayan S; Sri Balasubashini M; Somasundaram ST; Balasubramanian T
Toxicon; 2008 Jan; 51(1):157-61. PubMed ID: 17936322
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): II--Involvement of NK cells and adoptive immunotherapy.
Orraca ZM; Ríos-Olivares E; Carrasco-Canales JA; Aquino E; Marchand AM; Colón JI
Bol Asoc Med P R; 1989 Jul; 81(7):254-8. PubMed ID: 2775402
[TBL] [Abstract][Full Text] [Related]
34. Tumor inhibition by titanocene complexes: activity against sarcoma 180.
Köpf-Maier P; Preiss F; Marx T; Klapötke T; Köpf H
Anticancer Res; 1986; 6(1):33-7. PubMed ID: 3954328
[TBL] [Abstract][Full Text] [Related]
35. Pseudo-halide derivatives of titanocene: synthesis and cytotoxicity studies.
Claffey J; Deally A; Gleeson B; Hogan M; Méndez LM; Müller-Bunz H; Patil S; Wallis D; Tacke M
Metallomics; 2009 Nov; 1(6):511-7. PubMed ID: 21305159
[TBL] [Abstract][Full Text] [Related]
36. The effect of recombinant human tumor necrosis factor-alpha on Ehrlich ascites tumor growth.
Terlikowski S; Sulkowska M; Nowak HF
J Environ Pathol Toxicol Oncol; 2002; 21(1):87-92. PubMed ID: 11934018
[TBL] [Abstract][Full Text] [Related]
37. Protective effect of fungal growth product (6MFA), assessed therapeutically against Ehrlich's ascites tumor in Swiss mice.
Mall SA; Zaidi SI; Hussain MM; Singh KP; Mathur N; Gupta BM
J Biol Regul Homeost Agents; 1991; 5(2):45-51. PubMed ID: 1897382
[TBL] [Abstract][Full Text] [Related]
38. Antineoplastic and cytogenetic effects of chlorpromazine on human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo.
Lialiaris TS; Papachristou F; Mourelatos C; Simopoulou M
Anticancer Drugs; 2009 Sep; 20(8):746-51. PubMed ID: 19584706
[TBL] [Abstract][Full Text] [Related]
39. Growth and differentiation of bone marrow hematopoietic cells in mice bearing Ehrlich ascite tumor and treated with Dicyclopentadienildichlorotitanium (IV).
Valadares MC; Klein SI; Zyngier S; Queiroz ML
Int J Immunopharmacol; 1998 Oct; 20(10):573-81. PubMed ID: 9839661
[TBL] [Abstract][Full Text] [Related]
40. Signaling pathways implicated in hematopoietic progenitor cell proliferation and differentiation.
Bugarski D; Krstic A; Mojsilovic S; Vlaski M; Petakov M; Jovcic G; Stojanovic N; Milenkovic P
Exp Biol Med (Maywood); 2007 Jan; 232(1):156-63. PubMed ID: 17202596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
